BOSTON, MA (February 8, 2022) — Valo Health, LLC (“Valo”), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, today announced that its CEO and Founder, David Berry, M.D. PhD, will participate in a panel discussion at the BIO CEO & Investor Conference being held in New York, NY and virtually, on February 14, 2022 at 10:00 AM regarding “Venture Investor Trends in Biotech.”
For more information about the conference, please visit the conference website. A video webcast of the presentation will be available for viewing on-demand for those registered for the event.
About Valo Health, Inc.
Valo Health, LLC (“Valo”) is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence (“AI”) computation. As a digitally native company, Valo aims to full integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com.
Investors: Graeme Bell, Chief Financial Officer
Media: Jennifer Hanley, VP Corporate Communications